Fremanezumab in Children and Adolescents with Episodic Migraine - Part 1
Release Date: 02/12/2026
Navigating the Residency Application Process: Key Takeaways for Aspiring Neurologists
Neurology Minute
Casey Kozak discusses the process of applying to neurology residency. This episode offers insights for applicants and for neurologists who guide and mentor the next generation of neurologists.
info_outline
Trends in Head CT Use in US Emergency Department Patients
Neurology Minute
Dr. Andy Southerland and Dr. Layne Dylla discuss the trends in head CT use in US emergency departments from 2007 to 2022, highlighting disparities, regional variations, and the potential role of AI in optimizing imaging decisions. Show citations: Dylla L, Krothapalli N, Tu L, et al. Trends in Head CT Use in US Emergency Department Patients From 2007 to 2022: A Nationwide Analysis. Neurology. 2025;105(12):e214347. doi:
info_outline
A Discussion with Dr. Alison Christy: 2026 Ted Burns Humanism in Neurology Award Winner
Neurology Minute
Dr. Stacey Clardy talks with Dr. Alison Christy, the recipient of the 2026 Ted Burns Humanism in Neurology Award, about her inspiring career, innovative approaches to neurology education, and how she fosters compassion and creativity in medicine.
info_outline
Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021
Neurology Minute
Dr. Tesha Monteith talks with Ayesha Sohail about her abstract titled "Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021: An Analysis of Epidemiology, Trends, and Socioeconomic Disparities." Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 3
Neurology Minute
In the final episode of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the study results and their implications for improving clinical practice. Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss how this technology was developed and how it has evolved. Read more about this abstract on the .
info_outline
2026 AAN President's Award Recipient - Dr. Walter J. Koroshetz
Neurology Minute
Dr. Greg Cooper talks with Dr. Walter J. Koroshetz about his advice for early neurologists. Read more about the .
info_outline
A Path to Preventing Cognitive Impairment Due to Alzheimer's Disease
Neurology Minute
Dr. Greg Cooper and Dr. Eric Reiman discuss emerging antibody therapies for preclinical Alzheimer's disease and the clinical, regulatory, and equity considerations shaping prevention trials and future care. Show citation: Reiman EM, Alexander RC, Langbaum JB, et al. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. Lancet Neurol. 2026;25(3):268-278. doi:
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 1
Neurology Minute
In the first part of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the background and evolving terminology around circulating tumor DNA, cell‑free DNA and CSF‑based testing in neurology. Read more about this abstract on the .
info_outline
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the clinical trial design, including the objectives and methods. Read more about this abstract on the .
info_outlineIn part one of this two-part series, Dr. Tesha Monteith and Dr. Andrew Hershey summarize findings from the SPACE trial evaluating fremanezumab in adolescents and children with migraine.
Show citation:
Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546
Show transcript:
Dr. Tesha Monteith:
Hi, this is Tesha Monteith with the Neurology Minute. I'm here with Andrew Hershey, Professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. We're here talking about his new paper published in the New England Journal of Medicine, Fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, thank you for being on our Neurology Minutes.
Dr. Andrew Hershey:
Thank you for inviting me.
Dr. Tesha Monteith:
Can you summarize the findings of the space trial investigating Fremanezumab for adolescents and children with migraine?
Dr. Andrew Hershey:
This is one of the four monoclonal antibodies against CGRP, or it's this receptor that had been proven effective for adults. And it's the first one, the formazepam, that's been able to report its effectiveness in children and adolescents with less than 15 headache days per month. This study looked at over 200 children adolescents that were in a double-blinded randomized placebo controlled study. And reached its primary, as well as its secondary endpoint of a reduction compared to placebo. And the number of attacks of migraine per month, as well as a greater than 50% reduction in the number of headache attacks per month, with minimal to no side effects, the most notable side effect being injection site erythema.
Dr. Tesha Monteith:
Great. Thank you so much for providing that update. Do check out the full podcast for more details about his paper and the treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.